成人应用伏立康唑的群体药动学研究进展

doi:10.12092/j.issn.1009-2501.2019.09.009

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (9): 1015-1023.doi: 10.12092/j.issn.1009-2501.2019.09.009

成人应用伏立康唑的群体药动学研究进展

刘思敏^1,2，蔡俊¹，李慧馨^1,2，杨立³，赵燕³，张晋萍¹

¹南京大学医学院附属鼓楼医院药学部，南京 210008，江苏；²中国药科大学基础医学与临床药学学院，南京 210009，江苏；³南京大学医学院附属鼓楼医院老年科，南京 210008，江苏

收稿日期:2019-05-22 修回日期:2019-08-19 出版日期:2019-09-26 发布日期:2019-09-26
通讯作者: 张晋萍，女，硕士,主任药师，研究方向：临床药学。 Tel：025-83106666 E-mail: zjp16500@163.com
作者简介:刘思敏，女，硕士研究生,研究方向：临床药学。 Tel：025-66056666 E-mail: abc12394@126.com
基金资助:
南京药学会-常州四药医院药学科研基金（2017YX003）；江苏省干部保健科研课题（BJ18007）

Research progress in population pharmacokinetics of voriconazole in adults

LIU Simin^1,2, CAI Jun ¹, LI Huixin ^1,2, YANG Li³, ZHAO Yan ³, ZHANG Jinping ¹

¹Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing 210008, Jiangsu, China；²Department of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, Jiangsu, China；³ Department of Geriatrics, Nanjing Drum Tower Hospital, Nanjing 210008, Jiangsu, China

Received:2019-05-22 Revised:2019-08-19 Online:2019-09-26 Published:2019-09-26

摘要/Abstract

摘要：

目的:伏立康唑抗真菌活性强，抗真菌谱广，但其药动学呈现高度变异性。本文基于群体药动学模型对伏立康唑的药动学特征进行描述，为伏立康唑的个体化用药提供理论依据。方法:通过对中国知网、Pubmed、Web of Science等数据库查找伏立康唑群体药动学研究文献进行汇总分析，描述伏立康唑药动学特征。结果:9篇文献报道伏立康唑的群体药动学模型为一房室模型，4篇文献为二房室模型。伏立康唑代谢的主要影响因素为年龄、体质量、CY2C19基因型、肝功能和合并用药。结论:伏立康唑个体间存在相当大的差异性。对于特殊人群，制定个性化给药方案尤为重要。

关键词: 伏立康唑, 药动学, 群体药动学, 影响因素

Abstract:

AIM: Voriconazole has strong antifungal activity and broad antifungal spectrum, but its pharmacokinetics is highly variable due to various factors. In this paper, the pharmacokinetic characteristics of voriconazole were described based on the population pharmacokinetic model, which provided a theoretical basis for the individualized use of voriconazole. METHODS: The pharmacokinetics of voriconazole was characterized by searching the literatures of voriconazole population pharmacokinetics in CNKI, Pubmed and Web of Science. RESULTS:Nine studies reported the PPK model of voriconazole was one-compartment models and 4 studies were two-compartment models. The main influencing factors of voriconazole pharmacokinetics were age, body weight, CY2C19 phenotype, liver function and concomitant medication. CONCLUSION: There is considerable variation between voriconazole individuals. For specific populations, it is especially important to develop a personalized dosing regimen.

Key words: voriconazole, pharmacokinetics, population pharmacokinetics, influencing factors

中图分类号:

R969.1

刘思敏，蔡俊，李慧馨，杨立，赵燕，张晋萍. 成人应用伏立康唑的群体药动学研究进展[J]. 中国临床药理学与治疗学, 2019, 24(9): 1015-1023.

LIU Simin, CAI Jun, LI Huixin, YANG Li, ZHAO Yan, ZHANG Jinping. Research progress in population pharmacokinetics of voriconazole in adults[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1015-1023.

参考文献

［1］Gegorge D, Miniter P, Andriole VT. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis［J］. Antimicrob Agents Chemother,1996,40:86-91.
［2］Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis［J］. Clin Infect Dis, 2002, 34(5):563-571.
［3］Miyakis S, Van Hal SJ, Solvag CJS, et al. Clinician ordering practices for voriconazole therapeutic drug monitoring: Experiences of a referral laboratory［J］. Ther Drug Monit, 2010, 32(5):661-664.
［4］余静洁,杨四涛,周星,等.基于伏立康唑血药浓度监测成功干预药物相互作用3例［J］.医药导报,2017，36(8):879-883.
［5］张寒娟,谢悦旭,任彤,等.根据治疗药物监测指导伏立康唑个体化用药的案例分析［J］.药学服务与研究, 2019,19(2):129-132.
［6］Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole［J］. Drug Metab Dispos,2003,31:540-547.
［7］US Food and Drug Administration. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review: voriconazole (Vfend)［R/OL］ . ( 2019-08-19 ) https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021464s000_021466s000_Vfend_biopharmr.pdf
［8］Michael JD, Gerd M, Johanna W,et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing［J］. J Antimicrob Chemother, 2014,69:1633-1641.
［9］Liu P, Diane RM. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis［J］. Antimicrob Agents Chemother, 2014,58(8):4718-4726.
［10］Wang TT, Chen SY, Sun JY, et al.Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungalin fections［J］. J Antimicrob Chemother, 2014,69: 463-470.
［11］Pascual A , Csajka C , Buclin T , et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infections［J］. Clin Infect Dis, 2012, 55(3):381-390.
［12］王柠柠,梁武,颜苗,等.在本院患者中建立伏立康唑群体药物代谢动力学模型的初步探索［J］. 中南药学,2015,13(11):1174-1177.
［13］Chen WY, Xie H, Liang FH, et al. Population pharmacokinetics in China: The dynamics of intravenous voriconazole in critically ill patients with pulmonary disease［J］. Biol Pharm Bull,2015,38:996-1004.
［14］Chen C, Yang T, Li X, et al. Population pharmacokinetics of voriconazole in Chinese patients with hematopoietic stem cell transplantation［J］. Eur J Drug Metab Pharmacokinet, 2019, https://doi.org/10.1007/s13318-019-00556-w.
［15］Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients［J］. Antimicrob Agents Chemother, 2010, 54(10):4424-4431.
［16］Han K, Bies R, Johnson H, et al. Population pharmacokinetic evaluation with external validation and bayesian estimator of voriconazole in liver transplant recipients［J］. Clin Pharmacokinet,2011,50(3): 201-214.
［17］Li ZW, Peng FH, Yan M, et al. Impact of CYP2C19 genotype and liver function on voriconazole pharmacokinetics in renal transplant recipients［J］. Ther Drug Monit,2017,39(4):422-428.
［18］Lin XB, Li ZW, Yan M, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients［J］. Brit J Clin Pharmacol,2018,84(7):1587-1597.
［19］李紫薇,颜苗,彭风华,等.伏立康唑在肾移植患者中的群体药动学研究［J］.中国医院药学杂志,2017,37(3):221-226.
［20］Christenson JT, Schmuziger M, Maurice J, et al. Postoperative visceral hypotension the common cause for gastrointestinal complications after cardiac surgery［J］. Thorac Cardiovasc Surg, 1994,42 (3): 152-159.
［21］Kennedy JM, Riji AM. Effects of surgery on the pharmacokinetic parameters of drugs［J］. Clin Pharmacokinet,1998,35 (4): 293-312.
［22］Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications［J］. Antimicrob Agents Chemother,2009,53:24-34.
［23］王晶晶,何瑾,王露婕,等.61例伏立康唑血药浓度结果分析［J］.中国医院药学杂志,2016, 36(9):770-773.

[1]	武玉洁, 赵程程, 席庆. 蒙特卡洛模拟评价替加环素治疗革兰阴性菌感染给药方案[J]. 中国临床药理学与治疗学, 2023, 28(9): 1027-1033.
[2]	王鑫, 邬国栋, 安明, 李刚, 刘洋. 文拉法辛相关PK-PD关系及影响因素研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 788-795.
[3]	钱锦, 王峰岩. 老年急性心肌梗死患者PCI术后血清NT-proBNP水平的影响因素并分析其对近期预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(6): 658-665.
[4]	黄志伟, 李熠, 徐晓勇, 张蕾, 沈一峰, 李华芳. 五种群体药动学分析工具计算结果的比较[J]. 中国临床药理学与治疗学, 2023, 28(5): 525-535.
[5]	燕强勇, 向大雄, 朱荣华, 杨玲凤, 阳喜定, 李晶晶, 范晓, 刘赛, 熊守军, 方平飞. 盐酸西那卡塞片在中国健康人群的生物等效性研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 171-177.
[6]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[7]	李雪静, 江金平, 李思凝, 万林飞, 周响响, 杨梿, 兰轲. 一项在中国精神分裂症受试者中评估氯氮平片的生物等效性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1121-1130.
[8]	张进华, 刘茂柏, 蔡铭智, 郑英丽, 劳海燕, 向倩, 都丽萍, 朱珠, 董婧, 左笑丛, 李新刚, 尚德为, 陈冰, 叶岩荣, 王玉珠, 高建军, 张健, 陈万生, 谢海棠, 焦正. 模型引导的华法林精准用药：中国专家共识（2022版）[J]. 中国临床药理学与治疗学, 2022, 27(11): 1201-1212.
[9]	郭胜杰, 管汐蕊, 曹文莉, 梁思成, 齐晓怡, 葛广波, 吕沐瀚. 尿苷二磷酸葡醛酸转移酶介导的胆汁酸代谢过程及其内源和外源影响因素研究进展[J]. 中国临床药理学与治疗学, 2022, 27(1): 102-107.
[10]	贾元威, 沈杰, 储冀汝, 张翠锋, 谢海棠, 杨斌, 李相鸿, 郑丹丹, 赵静惠. 豆腐果苷及其代谢产物时辰药动学研究[J]. 中国临床药理学与治疗学, 2021, 26(9): 986-994.
[11]	彭敏, 黄攀豪, 邓银华, 刘文, 李威, 于珍, 夏青, 谢悦良. 造血干细胞移植患者伏立康唑稳态谷浓度监测及其影响因素分析[J]. 中国临床药理学与治疗学, 2021, 26(6): 640-646.
[12]	徐国防, 高盼, 刘平, 赖耀文, 李广辉, 赵岳, 张永玲, 李晓苏, 齐琦. 肿瘤患者个体差异对卡培他滨药物代谢动力学影响[J]. 中国临床药理学与治疗学, 2021, 26(3): 305-311.
[13]	章思亮, 胡琳璘, 邵华, 陈西敬. 性别差异对精神药物作用影响的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(3): 324-331.
[14]	张苗, 刘倩, 么雪婷, 刘东阳. 基于口服吸收生理药动学模型的创新药早期临床食物影响研究探索[J]. 中国临床药理学与治疗学, 2021, 26(12): 1426-1429.
[15]	焦正, 李新刚, 尚德为, 董婧, 左笑丛, 陈冰, 刘剑敏, 潘雁, 周田彦, 张菁, 刘东阳, 李禄金, 方翼, 马广立, 丁俊杰, 赵维, 陈锐, 相小强, 王玉珠, 高建军, 谢海棠, 胡蓓, 郑青山. 模型引导的精准用药：中国专家共识（2021版）[J]. 中国临床药理学与治疗学, 2021, 26(11): 1215-1228.

成人应用伏立康唑的群体药动学研究进展

Research progress in population pharmacokinetics of voriconazole in adults

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价